Cortes Lacassie syndrome
Cortes Lacassie syndrome is a rare genetic disorder characterized by a combination of distinctive craniofacial abnormalities, skeletal anomalies, and neurological impairments. The syndrome was first described by Cortes and Lacassie in the early 21st century.
Clinical Features[edit | edit source]
Individuals with Cortes Lacassie syndrome typically present with a range of clinical features, including:
- Microcephaly (abnormally small head size)
- Facial dysmorphism (distinctive facial features)
- Intellectual disability
- Growth retardation
- Skeletal abnormalities such as scoliosis and joint hypermobility
- Seizures and other neurological impairments
Genetics[edit | edit source]
Cortes Lacassie syndrome is believed to follow an autosomal recessive pattern of inheritance. This means that an individual must inherit two copies of the mutated gene, one from each parent, to be affected by the disorder. The specific gene or genes involved in Cortes Lacassie syndrome have not yet been identified.
Diagnosis[edit | edit source]
The diagnosis of Cortes Lacassie syndrome is primarily based on clinical evaluation and the presence of characteristic features. Genetic testing may be used to confirm the diagnosis and to identify the specific genetic mutation responsible for the disorder.
Management[edit | edit source]
There is currently no cure for Cortes Lacassie syndrome. Management of the condition is symptomatic and supportive, focusing on improving the quality of life for affected individuals. This may include:
- Physical therapy to address motor skills and mobility issues
- Occupational therapy to assist with daily living activities
- Speech therapy to improve communication skills
- Anticonvulsant medications to manage seizures
- Regular monitoring and treatment of associated medical conditions
Prognosis[edit | edit source]
The prognosis for individuals with Cortes Lacassie syndrome varies depending on the severity of the symptoms and the presence of associated medical conditions. Early intervention and supportive care can improve outcomes and enhance the quality of life for affected individuals.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
-
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD